These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
151 related articles for article (PubMed ID: 7685953)
21. Efficacy and toxicity of FK 506 for the treatment of resistant rejection in liver transplant patients. Hebert MF; Ascher NL; Lake JR; Roberts JP Transplant Proc; 1991 Dec; 23(6):3109-10. PubMed ID: 1721373 [No Abstract] [Full Text] [Related]
30. FK 506 for rescue treatment of acute and chronic rejection in liver allograft recipients. Shaw BW; Markin R; Stratta R; Langnas A; Donovan J; Sorrell M Transplant Proc; 1991 Dec; 23(6):2994-5. PubMed ID: 1721338 [No Abstract] [Full Text] [Related]
31. Effect of HLA matching and T- and B-cell crossmatch on acute rejection and graft survival following liver transplantation. Chen M; Wade J; Levy GA; Greig PD Transplant Proc; 1994 Oct; 26(5):2695-6. PubMed ID: 7940844 [No Abstract] [Full Text] [Related]
32. Comparison of FK 506- and cyclosporine-based immunosuppression: FK 506 therapy significantly reduces the incidence of acute, steroid-resistant, refractory, and chronic rejection whilst possessing a comparable safety profile. European FK 506 Multicenter Liver Study Group. Bismuth H Transplant Proc; 1995 Feb; 27(1):45-9. PubMed ID: 7533415 [No Abstract] [Full Text] [Related]
33. Rejection: FK 506 for rescue or maintenance. Klintmalm GB; Gibbs JF; McMillan R; Backman L; Levy M; Goldstein RM; Husberg BS; Holman MJ; Gonwa TA Transplant Proc; 1993 Apr; 25(2):1914-5. PubMed ID: 7682356 [No Abstract] [Full Text] [Related]
34. Long-term outcome of liver transplants for chronic hepatitis C: a 10-year follow-up. Neumann UP; Berg T; Bahra M; Puhl G; Guckelberger O; Langrehr JM; Neuhaus P Transplantation; 2004 Jan; 77(2):226-31. PubMed ID: 14742986 [TBL] [Abstract][Full Text] [Related]
35. Liver transplantation in positive cytotoxic crossmatch cases using FK506, high-dose steroids, and prostaglandin E1. Takaya S; Iwaki Y; Starzl TE Transplantation; 1992 Nov; 54(5):927-9. PubMed ID: 1279851 [No Abstract] [Full Text] [Related]
36. 12-month follow-up analysis of a multicenter, randomized, prospective trial in de novo liver transplant recipients (LIS2T) comparing cyclosporine microemulsion (C2 monitoring) and tacrolimus. Levy G; Grazi GL; Sanjuan F; Wu Y; Mühlbacher F; Samuel D; Friman S; Jones R; Cantisani G; Villamil F; Cillo U; Clavien PA; Klintmalm G; Otto G; Pollard S; McCormick PA Liver Transpl; 2006 Oct; 12(10):1464-72. PubMed ID: 17004259 [TBL] [Abstract][Full Text] [Related]
37. Tacrolimus (FK 506) therapy is associated with a significant reduction in immunosuppressive treatment failures following primary liver transplantation. Bechstein WO; Neuhaus P; McMaster P; Calne R; Pichlmayr R; Otto G; Williams R; Ericzon BG; Bismuth H Transplant Proc; 1996 Apr; 28(2):1008-10. PubMed ID: 8623211 [No Abstract] [Full Text] [Related]
38. Rejection and survival after total orthotopic liver-small bowel allotransplantation in pigs immunosuppressed with FK 506. Velio P; Tarantino C; Bertoglio C; Guffanti E; Bardella MT; Biffi R; Andreoni B; Rossi G; Gatti S; Piazzini A; Fassati LR; Galmarini D Transplant Proc; 1996 Oct; 28(5):2529-30. PubMed ID: 8907936 [No Abstract] [Full Text] [Related]
39. Strategy of FK 506 therapy in liver transplant patients: effect of graft function. Abu-Elmagd KM; Fung JJ; Alessiani M; Jain A; Takaya S; Venkataramanan R; Warty VS; Shannon W; Todo S; Tzakis A Transplant Proc; 1991 Dec; 23(6):2771-4. PubMed ID: 1721272 [No Abstract] [Full Text] [Related]
40. OKT3 vs FK 506 rescue management of acute steroid-resistant and chronic rejection. Platz KP; Mueller AR; Zytowski M; Bechstein WO; Blumhardt G; Lobeck H; Neuhaus P Transplant Proc; 1995 Feb; 27(1):1111-3. PubMed ID: 7533357 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]